PMID- 30177632
OWN - NLM
STAT- MEDLINE
DCOM- 20181211
LR  - 20181211
IS  - 1422-0067 (Electronic)
IS  - 1422-0067 (Linking)
VI  - 19
IP  - 9
DP  - 2018 Sep 3
TI  - The Use of Vascular Endothelial Growth Factor Inhibitors and Complementary 
      Treatment Options in Polypoidal Choroidal Vasculopathy: A Subtype of Neovascular 
      Age-Related Macular Degeneration.
LID - 10.3390/ijms19092611 [doi]
LID - 2611
AB  - Polypoidal choroidal vasculopathy (PCV) is a subtype of neovascular age-related 
      macular degeneration (AMD; nAMD) which occurs more commonly in Asian populations 
      as compared to Caucasians. PCV and nAMD share pathological mechanisms, including 
      pathological expression of vascular endothelial growth factor (VEGF). The advent 
      of anti-vascular endothelial growth factor (VEGF) revolutionized the treatment of 
      nAMD. Despite being a subtype of nAMD, PCV responds less well to VEGF inhibitors; 
      thus, photodynamic therapy (PDT) in combination with anti-VEGF treatment may be 
      considered. This review aims to summarize the current evidence for the treatment 
      of PCV, especially whether VEGF inhibitors should be used alone or in combination 
      with PDT.
FAU - Teo, Kelvin Yi Chong
AU  - Teo KYC
AD  - Singapore National Eye Centre, Singapore 168751, Singapore. kelvinteo@mac.com.
AD  - Singapore Eye Research Institute, Singapore 169856, Singapore. kelvinteo@mac.com.
AD  - Sydney Eye Hospital Foundation, Sydney Eye Hospital, Sydney 2000, Australia. 
      kelvinteo@mac.com.
FAU - Gillies, Mark
AU  - Gillies M
AD  - The Save Sight Institute, Sydney Medical School, University of Sydney, Sydney 
      2000, Australia. mark.gillies@sydney.edu.au.
FAU - Fraser-Bell, Samantha
AU  - Fraser-Bell S
AUID- ORCID: 0000-0001-5646-9359
AD  - The Save Sight Institute, Sydney Medical School, University of Sydney, Sydney 
      2000, Australia. sfraserbell@gmail.com.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20180903
PL  - Switzerland
TA  - Int J Mol Sci
JT  - International journal of molecular sciences
JID - 101092791
RN  - 0 (Angiogenesis Inhibitors)
RN  - 0 (Vascular Endothelial Growth Factor A)
SB  - IM
MH  - Angiogenesis Inhibitors/therapeutic use
MH  - Animals
MH  - Choroidal Neovascularization/*drug therapy/therapy
MH  - Humans
MH  - Macular Degeneration/*drug therapy/therapy
MH  - Photochemotherapy
MH  - Vascular Endothelial Growth Factor A/*antagonists & inhibitors
PMC - PMC6165414
OTO - NOTNLM
OT  - AMD
OT  - PCV
OT  - anti-VEGF
OT  - photodynamic therapy
OT  - polypoidal choroidal vasculopathy
COIS- The authors declare no conflict of interest.
EDAT- 2018/09/05 06:00
MHDA- 2018/12/12 06:00
PMCR- 2018/09/01
CRDT- 2018/09/05 06:00
PHST- 2018/07/13 00:00 [received]
PHST- 2018/08/17 00:00 [revised]
PHST- 2018/08/27 00:00 [accepted]
PHST- 2018/09/05 06:00 [entrez]
PHST- 2018/09/05 06:00 [pubmed]
PHST- 2018/12/12 06:00 [medline]
PHST- 2018/09/01 00:00 [pmc-release]
AID - ijms19092611 [pii]
AID - ijms-19-02611 [pii]
AID - 10.3390/ijms19092611 [doi]
PST - epublish
SO  - Int J Mol Sci. 2018 Sep 3;19(9):2611. doi: 10.3390/ijms19092611.